Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

HEALWELL AI Strengthens Board with Ian Kidson Appointment

Tipranks - Thu Dec 11, 2025

Claim 50% Off TipRanks Premium and Invest with Confidence

HEALWELL AI ( (TSE:AIDX) ) has provided an update.

HEALWELL AI has appointed Ian Kidson to its Board of Directors, bringing his extensive experience in financial, governance, and healthcare corporate leadership to the company. This strategic move is expected to bolster HEALWELL’s mission of advancing healthcare through early disease detection and improve its market positioning by leveraging Kidson’s expertise in guiding organizations through growth and transformation.

The most recent analyst rating on (TSE:AIDX) stock is a Hold with a C$0.94 price target. To see the full list of analyst forecasts on HEALWELL AI stock, see the TSE:AIDX Stock Forecast page.

Spark’s Take on TSE:AIDX Stock

According to Spark, TipRanks’ AI Analyst, TSE:AIDX is a Neutral.

HEALWELL AI’s overall score is driven by strong revenue growth and strategic corporate actions. However, significant challenges in profitability, cash flow, and technical indicators weigh heavily on the stock’s potential.

To see Spark’s full report on TSE:AIDX stock, click here.

More about HEALWELL AI

HEALWELL AI is a healthcare artificial intelligence company focused on preventative care. The company aims to improve healthcare and save lives through early identification and detection of diseases. It develops and commercializes advanced clinical decision support systems to help healthcare providers detect rare and chronic diseases, improve practice efficiency, and enhance patient health outcomes. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol ‘AIDX’ and on the OTC Exchange under ‘HWAIF’.

Average Trading Volume: 462,097

Technical Sentiment Signal: Sell

Current Market Cap: C$296.1M

Learn more about AIDX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.